& lt ; Praxis Biologics Inc > said filed registration statement Securities Exchange Commission initial public offering 1.5 mln share common .
It said offering managed Shearson Lehman Brothers Inc Merrill Lynch Capital Markets .
Praxis said use proceeds fund product research development cost initially focus vaccine infant young child .
Reuter & # 3 ; 